Amendment to BAA Outlines New DTRA Funding Opportunities to Develop Novel Technologies and Medical Countermeasures Against Weapons of Mass Destruction (WMD) and Emerging Threats
The Defense Threat Reduction Agency (DTRA) recently published an amendment to their Broad Agency Announcement (‘BAA”) No. HDTRA1-22-S-0003, which provides additional funding opportunities to identify and counter Weapons of Mass Destruction (WMD). WMD are defined as novel pathogens, new delivery technologies for chemical or biological weapons, or the use of traditional WMD material in novel ways.
DTRA seeks proposals that will advance their research, development, test, and evaluation (RDT&E) priorities across five main areas:
Understanding current and emerging WMD situations, threats, and capabilities
The first focus area seeks to develop technologies that will help identify, assess, and track chemical, biological, radiological, and nuclear (CBRN) threats. These new technologies may include modeling and assessment tools, forecasting methodologies, improved detection methods, and implementation of early warning systems.
Enabling effective and integrated WMD deterrence
This focus area seeks to strengthen early warning capabilities for WMD threats and develop innovative technologies that protect US weapons and minimize risk to the warfighter. Approaches to monitor and deter potential threats, as well as to prevent conflict escalation and further WMD deployment after first use, are also included here.
Controlling, disabling, and defeating current and emerging WMD threats
DTRA seeks to develop field-deployable solutions to mitigate risk to the warfighter from WMDs and to disarm adversary WMD programs. Technologies that equip the warfighter to prevail against WMDs on the battlefield and that prevent adversaries from acquiring expertise in WMDs are sought.
Protecting the force and mitigating crises from WMD
This focus area includes development of medical countermeasures, pretreatments, prophylaxes, vaccines, and therapeutics to protect against a broad range of emerging CBRN threats. State-of-the-art surveillance and exposure detection, as well as medical diagnostics and remote sensing and rapid field-identification capabilities, are also of interest to DTRA.
Enabling cross-cutting capabilities
DTRA is interested in enhancing artificial intelligence and machine learning capabilities to enable an increased speed of response against WMDs. Also included in this focus area is the development of better instrumentation and computational resources to support the countering of WMD threats.
For the first phase of interaction, respondents are asked to prepare a quad chart and 10-page white paper. Submissions are accepted on a rolling basis for the period in which the BAA is open, until February 2027. A subset of submissions from Phase I will be invited to submit a full proposal for Phase II.
If you are developing a novel technology or therapeutic medical countermeasures that you think might fall under one of the areas mentioned above, EverGlade can help you make that determination and pursue a successful contract. EverGlade Consulting is a national consulting firm helping clients navigate the federal landscape.
We work with technology-driven companies whose focus is to secure non-dilutive funding through the federal government. We offer services ranging from opportunity identification and funding opportunity proposal support through the implementation of systems to comply with federal regulations at agencies including BARDA, ASPR, NIH, DTRA, JPEO, and DARPA.
For additional information about EverGlade’s recent success, visit:
EverGlade Consulting Helps Land up to $1 Billion in BARDA Funding for Biotechnology Company
EverGlade Consulting Assists United Safety Technology, Inc. in Securing $97 Million DOD Award